Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Clinical trial NCT03309878 · COMPLETED

Trial details

NCT number: NCT03309878
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Recurrent Diffuse Large B-Cell Lymphoma Recurrent High Grade B-Cell Lymphoma Recurrent Transformed B-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory High Grade B-Cell Lymphoma Refractory Transformed B-Cell Non-Hodgkin Lymphoma

Start date: 2018-10-24
Primary completion: 2021-01-06
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.